Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

ABSTRACT:

Aim

To describe factors associated with treatment failure and frequency of resistance-associated substitutions (RAS).

Methods

Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfected patients starting a first direct-acting antiviral (DAA) regimen before February 2016 and included in the French ANRS CO13 HEPAVIH cohort were eligible. Failure was defined as: (1) non-response [HCV-RNA remained detectable during treatment, at end of treatment (EOT)]; and (2) relapse (HCV-RNA suppressed at EOT but detectable thereafter). Sequencing analysis was performed to describe prevalence of drug class-specific RAS. Factors associated with failure were determined using logistic regression models.

Results

Among 559 patients, 77% had suppressed plasma HIV-RNA < 50 copies/mL

SUBMITTER: Salmon D 

PROVIDER: S-EPMC6280155 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature